

T1 Food and Drug Administration-Approved Cancer Immunotherapies

Checkpoint Inhibitors	Approved to Treat	Companion (COM) or Complementary (COMP) Diagnostic
Ipilimumab (Yervoy)	Melanoma	
Pembrolizumab (Keytruda)	Melanoma, non-small cell lung cancer (NSCLC) non-squamous cell lung cancer, head and neck squamous cell carcinoma (SCCHN) classical hodgkin lymphoma (cHL) urothelial carcinoma; microsatellite instability-high (MSI-H) or mismatch-repair deficient (dMMR) cancers, gastric or gastroesophageal junction (GEJ) adenocarcinoma	PD-L1 IHC 22C3 pharmDx (COM)
Nivolumab (Opdivo)	Melanoma, NSCLC, renal cell carcinoma, SCCHN, cHL, urothelial carcinoma, MSI-H or dMMR colorectal cancer, hepatocellular carcinoma	PD-L1 IHC 28-8 pharmDx (COMP)
Atezolizumab (Tecentriq)	urothelial carcinoma, NSCLC	VENTANA PD-L1 (SP142) (COMP)
Avelumab (Bavencio)	Merkel cell carcinoma, urothelial carcinoma	
Durvalumab (Imfinzi)	urothelial carcinoma, NSCLC	VENTANA PD-L1 (SP263) (COMP)
CAR T Cell Therapies		
Axicabtagene ciloleucel (Yescarta)	B-cell non-Hodgkin lymphoma	
Tisagenlecleucel-T (Kymriah)	Pediatric acute lymphoblastic leukemia	

Sources:
<https://www.drugs.com/slideshow/immune-checkpoint-inhibitors-1249> (Accessed March 19, 2018)
<https://medi-paper.com/approved-immunotherapies/> (Accessed March 19, 2018)
<https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555930.htm> (Accessed March 19, 2018)
 Ther Drug Monit 2018;40:9-16